BioCardia (Nasdaq:BCDA) - Cotización, noticias y análisis

Resumen de acción BCDA

BioCardia, Inc, empresa de medicina regenerativa en fase clínica, se dedica al desarrollo de terapias celulares y derivadas de células para enfermedades cardiovasculares y pulmonares.

Acerca de la empresa

BCDA fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	1/6
Dividends	0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 68.59%

Los beneficios han crecido un 5% al año en los últimos 5 años

Análisis de riesgos

Tiene menos de 1 año de cash runway

Patrimonio neto negativo

Tiene unos ingresos inferiores a 1 millón de dólares ($477K)

No tiene una capitalización de mercado significativa ($10M)

+ 4 riesgos adicionales

Competidores de BioCardia, Inc.

Bionomics

NasdaqGM:BNOX

US$10.7m

Senti Biosciences

NasdaqCM:SNTI

US$13.3m

Molecular Templates

NasdaqCM:MTEM

US$11.2m

Avalo Therapeutics

NasdaqCM:AVTX

US$16.5m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for BioCardia
Historical stock prices
Current Share Price	US$0.38
52 Week High	US$2.92
52 Week Low	US$0.32
Beta	1.49
1 Month Change	-7.47%
3 Month Change	-21.61%
1 Year Change	-81.08%
3 Year Change	-89.48%
5 Year Change	-96.16%
Change since IPO	-97.23%

Noticias y actualizaciones recientes

Recent updates

Here's Why BioCardia, Inc.'s (NASDAQ:BCDA) CEO Compensation Is The Least Of Shareholders Concerns

Oct 12

BioCardia stock rises on contract for delivery products for BlueRock's cell therapies

Aug 24

Shareholders May Not Be So Generous With BioCardia, Inc.'s (NASDAQ:BCDA) CEO Compensation And Here's Why

Jun 08

Is BioCardia (NASDAQ:BCDA) In A Good Position To Deliver On Growth Plans?

May 20

BioCardia issued U.S. patent for Helix Biotherapeutic Delivery system

Dec 30

BioCardia slips 11% on launch of direct offering

Dec 16

Rentabilidad de los accionistas

	BCDA	US Biotechs	Mercado US
7D	2.4%	-1.2%	2.0%
1Y	-81.1%	-2.3%	22.3%

Rentabilidad vs. Industria: BCDA obtuvo unos resultados inferiores a los del sector US Biotechs , que el año pasado arrojó un rendimiento del -2.3%.

Rentabilidad vs. Mercado: BCDA obtuvo unos resultados inferiores a los del mercado US, que fue del 21.9% el año pasado.

Volatilidad de los precios

Is BCDA's price volatile compared to industry and market?
BCDA volatility
BCDA Average Weekly Movement	11.3%
Biotechs Industry Average Movement	11.4%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: El precio de las acciones de BCDA ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de BCDA ha disminuido de 28% a 12% en el último año, pero sigue siendo superior al 75% de los valores de US.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
n/a	18	Peter Altman	www.biocardia.com

BioCardia, una empresa de medicina regenerativa en fase clínica, se dedica al desarrollo de terapias celulares y derivadas de células para enfermedades cardiovasculares y pulmonares. Su principal candidato terapéutico es el CardiAMP, un sistema de terapia celular mononuclear autóloga para el tratamiento de la insuficiencia cardiaca y la isquemia miocárdica crónica; y la terapia celular alogénica para enfermedades cardiacas y pulmonares. La empresa también está desarrollando una plataforma terapéutica de células alogénicas, una terapia celular mesenquimal derivada de médula ósea expandida en cultivo en fase de investigación, que se encuentra en ensayo de fase I/II para el tratamiento de la insuficiencia cardiaca isquémica.

Resumen de fundamentos de BioCardia, Inc.

¿Cómo se comparan los beneficios e ingresos de BioCardia con su capitalización de mercado?
Estadísticas fundamentales de BCDA
Capitalización bursátil	US$10.12m
Beneficios(TTM)	-US$11.57m
Ingresos (TTM)	US$477.00k

21.2x

Ratio precio-ventas (PS)

-0.9x

Ratio precio-beneficio (PE)

¿Está BCDA sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de BCDA
Ingresos	US$477.00k
Coste de los ingresos	US$7.73m
Beneficio bruto	-US$7.25m
Otros gastos	US$4.32m
Beneficios	-US$11.57m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.43
Margen bruto	-1,519.71%
Margen de beneficio neto	-2,425.79%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado BCDA a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción BCDA

Recompensas

Análisis de riesgos

Competidores de BioCardia, Inc.

NasdaqGM:BNOX

US$10.7m

NasdaqCM:SNTI

US$13.3m

NasdaqCM:MTEM

US$11.2m

NasdaqCM:AVTX

US$16.5m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort

BioCardia, Inc., Annual General Meeting, May 20, 2024

New major risk - Financial position

Full year 2023 earnings: EPS and revenues miss analyst expectations

BioCardia, Inc. to Report Fiscal Year 2023 Results on Mar 27, 2024

BioCardia Receives Determination Letter from the Staff that the Company Fails to Regain Compliance with the MVLS Requirement

Recent updates

BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort

BioCardia, Inc., Annual General Meeting, May 20, 2024

New major risk - Financial position

Full year 2023 earnings: EPS and revenues miss analyst expectations

BioCardia, Inc. to Report Fiscal Year 2023 Results on Mar 27, 2024

BioCardia Receives Determination Letter from the Staff that the Company Fails to Regain Compliance with the MVLS Requirement

BioCardiaAnnounces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

Biocardia Reports Positive Interim Results from Phase III Cardiamp Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

BioCardia, Inc. Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA

New major risk - Market cap size

BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction

BioCardia, Inc. has filed a Follow-on Equity Offering in the amount of $2.75 million.

BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure

BioCardia, Inc. has filed a Follow-on Equity Offering in the amount of $1.3 million.

BioCardia, Inc. Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure

New major risk - Negative shareholders equity

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

BioCardia, Inc. Elects Bill Facteau as Class I Director

Here's Why BioCardia, Inc.'s (NASDAQ:BCDA) CEO Compensation Is The Least Of Shareholders Concerns

Biocardia, Inc. Announces Completion of Enrollment in Phase Iii Cardiamp Hf Trial and Plans for Cardiamp Hf Trial Ii

BioCardia Receives a Written Notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

BioCardia Receives a Written Notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

BioCardia, Inc. Announces Clarification and Next Steps on Its Autologous CardiAMP Cell Therapy Programs

Biocardia, Inc. Announces Interim Efficacy Results in Phase III Pivotal Cardiamp Cell Therapy Heart Failure Trial

BioCardia, Inc., Annual General Meeting, Oct 18, 2023

Consensus revenue estimates decrease by 74%, EPS upgraded

New major risk - Revenue size

Second quarter 2023 earnings: EPS in line with expectations, revenues disappoint

BioCardia, Inc. to Report First Half, 2023 Results on Aug 09, 2023

New major risk - Share price stability

Biocardia, Inc. Announces Dsmb Recommendation to Pause New Enrollment in Phase III Pivotal Cardiamp Cell Therapy Heart Failure Trial While Additional Blinded Data Is Collected

BioCardia, Inc. Completes Submission of Cardiamp Cell Therapy System in Heart Failure to Japan's Pharmaceutical Medical Device Agency

New minor risk - Share price stability

Insider recently bought US$177k worth of stock

Consensus revenue estimates increase by 86%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

BioCardia, Inc. to Report Q1, 2023 Results on May 10, 2023

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 24% to US$7.50

BioCardia, Inc. announced that it expects to receive $3.564989 million in funding

BioCardia, Inc. Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure

Consensus forecasts updated

Consensus forecasts updated

Price target decreased to US$9.88

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

BioCardia, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Insufficient new directors

Biocardia®, Inc. to Present New Data from Cardiamp Cell Therapy for Heart Failure Pivotal Trial At the Heart Failure Society of America Annual Meeting

BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial

BioCardia stock rises on contract for delivery products for BlueRock's cell therapies

Will BioCardia (NASDAQ:BCDA) Spend Its Cash Wisely?

Consensus revenue estimates increase by 138%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

BioCardia, Inc. to Report First Half, 2022 Results on Aug 10, 2022

BioCardia, Inc. Announces US Patent on Imaging System for Targeting Cardiac Therapies

Consensus EPS estimates fall by 15%

Consensus revenue estimates increase by 64%